摘要
目的探讨OX-LDL及HMG-CoA还原酶抑制剂辛伐他汀对人单核细胞(Mo)表达蛋白激酶C(PKC)活性和胞浆内游离钙([Ca2+]i)浓度的影响。方法Mo PKC活性采用 γ-32P-ATP磷酸转移法,细胞内游离钙采用 Fluo-3/Am荧光负载,流式细胞术检测。结果OX-LDL呈剂量依赖方式促进人 Mo PKC活性增加,12 min时达峰值,然后缓慢下降,20 min后仍维持较高水平,胞浆内[Ca2+]i升高分2个时相,即快速相和持续相。移去细胞外液钙,OX-LDL仍引起快速相,但持续相消失,而辛伐他汀能明显抑制OX-LDL.引起的Mo PKC活性增加,并降低持续相胞浆内钙水平,而对快速相无明显影响。结论OX-LDL能激活人单核细胞PKC活性与升高[Ca2+]i。OX- LDL刺激Mo[Ca2+]i升高的快速相是有胞浆钙池释放引起,持续相升高主要有胞外钙内流引起。辛伐他汀抑制Mo PKC活性可能是通过胞内钙水平变化起作用。
AIM To investigate the effect of OX- LDL and HMG-CoA reductase inhibitors simvastatin on PKC activity and cytosolic free Ca2+ in cultured human monocytes. METHOD The activity of PKC was determined by its ability to transfer phosphate fm [32P] ATP to lysine-rich histone and cytosolic free calcium[Ca2+]i was measured by flow cytometric analysis loading with the Ca2+ dye fluo3/Am.RE- SULTS OX-LDL increased PKC total activity in a dose-dependent manner with phase peaking at 12 min, then decreased slowly and maintained for at least 20 min, while OX-LDL induced biphasic [Ca2+ ], responses including the rapid initial transient phase and the sustained phase. Removal of extracellular Ca2+ did not inhibit the rapid initial transient phase of OX-LDL-induced rise. in [ Ca2+ ]i, but abol- abolished the sustained phase of [ Ca2+ ] i response to OX LDL. When simvastatin was added, the activity of PKC was markedly decreased and simvastatin did not impair the initial peak response to OX-LDL but sig- nificantly reduced the subsequent plateau phase. CONCLUSION OX-LDL can significantly activate the activity of PKC and elevate [Ca2+ ]i in monocytes. The rapid initial transient phase was the result of mobilization of [Ca2+ ], fm intracellular pool and sustained phase resulted from the influx of extracellular Ca2+. The inhibition of PKC activity induced by simvastatin may be contribute to the changes of intracellular Ca2+.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2001年第2期178-181,共4页
Chinese Pharmacological Bulletin
关键词
氧化低密度脂蛋白
辛伐他汀
单核细胞
蛋白激酶C
钙
oxidized low density lipoprotein
sim- vastatin
monocytes
protein kinase C
calcium Dept of Cardiovasology, the Fourth Peoples Hospital of Zhenjiang, Zhenjiang 212001